Stueland will remain in an advisory role through January 2027 to help with the transition, GeneDx said Wednesday. Cunningham joined Quanterix in January as its president, CEO and a board member, making his tenure there less than a year.
Quanterix said Jim Gute, its chief commercial officer since August, will serve as interim president and CEO while the company searches for a successor. It will consider both internal and external candidates. Quanterix shares recently fell 14% to $2.45 in premarket trading.
GeneDx said Cunningham’s compensation will include an initial annual base salary of $750,000, a $1.05 million sign-on bonus and an annual bonus targeted at 100% of his base pay.




Comments (0)
No comments yet. Be the first!